Greg Mann

Investor Relations Contact at NKARTA, INC.

Health Technology

Profile

Greg Mann is currently working as the Media & Investor Relations Contact at Nkarta, Inc. He previously worked as the Director-Investor Relations at Abgenix, Inc., Executive Director-IR & Corporate Communications at FibroGen, Inc., and Vice President-Investor Relations at Kite Pharma, Inc.

Greg Mann active positions

Companies	Position	Start
NKARTA, INC.	Investor Relations Contact	31/01/2020

All active positions of Greg Mann

Former positions of Greg Mann

Companies	Position	End
Abgenix, Inc. Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA.	Investor Relations Contact	31/12/2005
KITE PHARMA INC	Investor Relations Contact	-
FIBROGEN, INC.	Investor Relations Contact	-

See the detail of Greg Mann's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Greg Mann's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
FIBROGEN, INC.	Health Technology
NKARTA, INC.	Health Technology

Private companies	2
Abgenix, Inc. Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA.	Health Technology
Kite Pharma, Inc. Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA.	Health Technology